Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | COMBI-i findings

Georgina Long, MD, PhD, FRACP, from The University of Sydney, Sydney, Australia, discusses the findings of the COMBI-i trial (NCT02967692), which investigated the safety and efficacy of the combination of an anti-PD-1 antibody, spartalizumab (PDR001), a BRAF inhibitor, dabrafenib and a MEK inhibitor, trametinib in unresectable or metastatic melanoma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.